Lung Cancer Biomarkers Predict Immunotherapy Success

Researchers have identified key biomarkers that predict improved clinical outcomes for patients with non-small-cell lung cancer (NSCLC) undergoing perioperative immune-based therapy. These findings stem from comprehensive exploratory analyses conducted on data from the phase III CheckMate 77T study, which investigated the efficacy of nivolumab, an immunotherapy drug, administered both before and after surgery for surgically resectable NSCLC. The study's results, published online on September 2, 2026, in Nature, indicate that the clearance of circulating tumor DNA (ctDNA) in the blood prior to surgery is a significant predictor of enhanced clinical response to nivolumab treatment.

The CheckMate 77T study enrolled patients with resectable NSCLC, a type of lung cancer that has not spread to distant parts of the body and can potentially be removed through surgery. The trial specifically examined the combination of nivolumab with chemotherapy given before surgery (neoadjuvant therapy) followed by nivolumab alone after surgery (adjuvant therapy). This perioperative approach aims to reduce the risk of cancer recurrence by targeting cancer cells both before and after the primary surgical intervention.

Biomarker analysis is crucial in precision medicine, particularly in oncology, as it helps to identify individuals who are most likely to benefit from specific treatments. Circulating tumor DNA (ctDNA) refers to fragments of DNA shed by cancer cells into the bloodstream. Detecting and quantifying ctDNA can provide insights into tumor burden, treatment response, and the presence of minimal residual disease. The finding that pre-surgical clearance of ctDNA correlates with improved outcomes suggests that patients who achieve a significant reduction or elimination of ctDNA before undergoing surgery may experience more durable responses to nivolumab therapy.

While the study highlights ctDNA clearance as a promising biomarker, the comprehensive exploratory analyses likely examined a range of other potential markers as well. These could include immune cell profiles, genetic mutations within the tumor, or other molecular signatures. The publication in Nature, a leading scientific journal, underscores the significance of these findings for the field of lung cancer treatment. Further validation and research may lead to the integration of these biomarkers into clinical practice, enabling oncologists to better select patients for nivolumab-based perioperative immunotherapy and personalize treatment strategies for improved patient prognoses. The study's methodology, involving a phase III trial, provides a robust foundation for these conclusions, as phase III trials are designed to confirm the efficacy and safety of new treatments in large patient populations.